Dostarlimab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Dostarlimab
Dostarlimab: Known uses and market status in Canada
Summary
The TxGNN deep-learning model produced no candidate indication with a score of 0.99 or higher for Dostarlimab, so there is currently no new predicted indication. The drug’s own recorded uses are listed below. They are not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| endometrial neoplasms | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02523434 | JEMPERLI | Valid |
Safety Considerations
- Drug Interactions: The interaction query completed with one pharmacology entry. It is a target record (PD-1, CD279) rather than an interaction with another drug, so it does not point to a clinically relevant drug interaction.
- Class-related concern: For autoimmune conditions such as the overlap syndrome of primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis, immune activation by PD-1 blockade is mechanistically counterproductive and a safety concern.
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.